Xeris Biopharma (XERS) - Net earnings per share (EPS TTM)

Xeris Biopharma focuses on developing convenient drug delivery systems for patients with rare pathologies. High supply chain reliability and temperature control guarantee product quality, while its status as an innovator strengthens physician trust. The rolling net income per share demonstrates efficient capital management, with -0.05 recorded as the baseline value for current yield.
Comprehensive metric breakdowns and analytics for Xeris Biopharma Inc (XERS)

High capacity utilization of Xeris Biopharma pharmaceutical facilities directly impacts net income, which is allocated per common share to assess the real return on equity. The current value of -0.05 reflects the final annual financial result stripped of market noise, allowing the annual net income per share trend to differentiate sustainable business growth from temporary fluctuations.